Primary efficacy outcome
Stroke, Thrombolysis, Cerebral Infarction
REGRESSION, CEREBRAL INFARCTION, STROKE
Treatment with intravenous tirofiban was associated with independent functional outcome (mRS 0 to 2) at 90 days in 54.3% (95 out of 175) patients in the tirofiban group and 44.0% (91 out of 207) patients (44.0%) in the placebo group (adjusted odds ratio [aOR], 1.58; 95% CI, 1.02–2.44; Efficacy and safety outcomes.CI, confidence interval; EQ‐5D‐5L, European Quality of Life 5‐Dimension 5‐level scale; eTICI, expanded Thrombolysis In Cerebral Infarction grade; IQR, interquartile range; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.Values were adjusted for age, baseline NIHSS score, baseline ASPECTS, occlusion site, and time from last known well to randomization.Values were calculated using ordinal logistic model.Values were calculated using linear regression model.Distribution of the Modified Rankin Scale score at 90 days.